

## Total Antioxidant Response and Oxidative Stress in Patients with Behçet's Disease

Ahmet IŞIK  
Süleyman Serdar KOCA

Firat University  
Faculty of Medicine  
Department of  
Rheumatology  
Elazığ-TÜRKİYE

It was shown that many antioxidants decrease in Behçet's disease (BD). Total antioxidant response (TAR), whose measurement method has been recently specified and developed, represents the total antioxidant properties of all antioxidants. This study aims to measure the antioxidant capacity in BD with TAR and to determine its relation with disease activity.

The study included 21 BD cases (10 active and 11 inactive) and 23 healthy volunteers as the control group. TAR and total peroxide (TP) were studied using appropriate methods and oxidative stress index (OSI) was calculated.

TAR level was  $1,04 \pm 0,07$  and  $1,16 \pm 0,08$  mmol Trolox eq./L in the BD group and in the control group, respectively; TP level was  $13,4 \pm 4,5$  and  $7,72 \pm 1,86$   $\mu\text{mol H}_2\text{O}_2/\text{L}$  in the BD group and in the control group, respectively; OSI value was  $1,45 \pm 0,52$  and  $0,67 \pm 0,18$  Arbitrary Units in the BD group and in the control group, respectively. When compared to the control group, TAR level was significantly lower and TP and OSI levels were significantly higher in the BD group ( $p < 0,001$ , for each). TAR level was negatively correlated with TP and OSI levels both in the BD group ( $r = -0,578$ ,  $p < 0,01$  and  $r = -0,552$ ,  $p < 0,01$ , respectively) and the control group ( $r = -0,469$ ,  $p < 0,05$  and  $r = -0,391$ ,  $p < 0,05$ , respectively). There was not any significant difference between active and inactive BD groups in terms of TAR, TP and OSI levels ( $p > 0,05$ , for each).

TAR is an appropriate method that can be used to determine the antioxidant capacity in BD.

**Key Words:** Behçet's Disease, Total Antioxidant Response, Total Peroxide, Oxidative Stress Index.

### Behçet Hastalığında Total Antioksidan Cevap ve Oksidatif Stres

Behçet hastalığı (BH)'nda birçok antioksidanın azaldığı ortaya konulmuştur. Ölçüm metodu son zamanlarda belirlenmiş ve geliştirilmiş olan total antioksidan cevap (TAR), tüm antioksidanların toplam antioksidan özelliklerini yansıtabilmektedir. Bu çalışmanın amacı, BH'nda antioksidan kapasiteyi TAR ile ölçmek ve hastalık aktivitesi ile olan ilişkisini belirlemektir.

Çalışmaya 21 BH olgusu (10 aktif, 11 inaktif) ile kontrol grubu olarak yaş ve cinsiyetleri uyumlu 23 sağlıklı gönüllü alındı. TAR ve total peroksit (TP) uygun yöntemler ile çalışıldı ve oksidatif stres indeksi (OSI) hesaplandı.

TAR düzeyi BH grubunda  $1,04 \pm 0,07$ , kontrol grubunda  $1,16 \pm 0,08$  mmol Trolox eq./L; TP düzeyi BD grubunda  $13,4 \pm 4,5$ , kontrol grubunda  $7,72 \pm 1,86$   $\mu\text{mol H}_2\text{O}_2/\text{L}$ ; OSI değeri BH grubunda  $1,45 \pm 0,52$ , kontrol grubunda  $0,67 \pm 0,18$  Arbitrary Unit olarak saptandı. Kontrol grubu ile karşılaştırıldığında, BH grubundaki TAR düzeyi düşüklüğü, TP ve OSI düzeyleri yüksekliği istatistiksel anlamlılıktaydı (herbirisini için;  $p < 0,001$ ). TAR düzeyi ile TP ve OSI düzeyleri arasında, hem BH grubunda (sırasıyla;  $r = -0,578$ ,  $p < 0,01$  ve  $r = -0,552$ ,  $p < 0,01$ ), hem de kontrol grubunda (sırasıyla;  $r = -0,469$ ,  $p < 0,05$  ve  $r = -0,391$ ,  $p < 0,05$ ) anlamlı negatif korelasyon vardı. Aktif ve inaktif BH grupları arasında; TAR, TP ve OSI düzeyleri açısından anlamlı farklılık yoktu (herbirisini için,  $p > 0,05$ ).

TAR, BH'nda antioksidan kapasiteyi belirlemek amacıyla kullanılabilir uygun bir yöntemdir.

**Anahtar Kelimeler:** Behçet Hastalığı, Total Antioksidan Cevap, Total Peroksit, Oksidatif Stres İndeksi.

### Introduction

Behçet's disease (BD) is a chronic relapsing inflammatory disease. It is characterized by recurrent oral aphthous ulcer, genital ulcer/scar, ocular inflammation, skin and joint signs (1). The etiology and pathogenesis of BD has not been known fully yet, but genetic, environmental and autoimmune factors are thought to be involved (2). The interest to reactive oxygen species (ROS), which can be produced as a result of normal aerobic metabolism and whose production by active neutrophils increases during inflammation, has been recently grown (3).

Activated neutrophils cause the production of non-radical ROS like hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) and singlet oxygen ( $^1\text{O}_2$ ), radical ROS like hydroxyl anion-radical ( $\text{OH}^\bullet$ ) and superoxide radical ( $\text{O}_2^\bullet$ ), and nitrogen-containing radicals like peroxynitrite ( $\text{ONOO}^-$ ) (3-7).

Geliş Tarihi : 29.05.2006  
Kabul Tarihi : 20.11.2006

### Yazışma Adresi

Süleyman Serdar KOCA  
Firat Üniversitesi  
Tıp Fakültesi  
Romatoloji Bilim Dalı  
23100  
Elazığ-TÜRKİYE

kocassk@yahoo.com

Polymorphonuclear leukocytes increase the production of hypochlorous acid (HOCl) from H<sub>2</sub>O<sub>2</sub> via myeloperoxidase enzyme (5-8). HOCl, in turn, causes tissue injury via sulphhydryl oxidation and protein decarboxylation, leading to oxidative modification of macromolecules in the tissues (7,8).

ROS lead to cell damage through its detrimental effects on peroxidation of double-chain fatty acids, protein and DNA, as well as, increase oxidative stress (3,4,7). Oxidants damage the antioxidant system, and thereby reduce the antioxidants levels (5-8).

In BD, it has been reported that antioxidants decrease as a result of increased ROS production and oxidative stress (3,6,9,10). Impaired oxidant/antioxidant balance is held responsible for the tissue damage in BD (11, 12). Furthermore, oxidative stress and lipid peroxidation (LPO) products have active part in the endothelial dysfunction and development of atherosclerosis (13,14). Chambers et al. (4) have demonstrated the presence of endothelial dysfunction in BD and have noted that endothelial dysfunction, a precursor of atherosclerosis, is associated with oxidative stress and LPO products.

Blood contains many antioxidant molecules which prevent and/or inhibit harmful free radical reactions (15). Exogenous antioxidants, like vitamin C and vitamin E, and endogenous antioxidant like albumin, bilirubin, uric acid and superoxide dismutase and glutathione peroxidase as the scavenger enzymes can protect the cell against the potentially harmful effects of oxidant agents (5,7,15). Concentrations of these antioxidants in the plasma can be measured one by one, but this procedure is time-consuming, labour-intensive and costly, and requires complicated techniques (16,17). On the other hand, total antioxidant response (TAR) whose measurement method has been recently specified and developed can reflect the total antioxidative state of the plasma (16,17). In this method, TAR of the plasma against especially potent free radical reactions, which strongly lead to oxidative damage of biomolecules such as lipids, proteins and DNA, is measured. In this study, we aimed to measure both the levels of some individual antioxidant components and the TAR levels in plasma

samples from active and inactive BD to evaluate their antioxidant status using a novel automated method (16,17). As a reciprocal measure, the total peroxide (TP) levels of the same plasma samples were also measured. The ratio of the plasma TP level to the TAR level was regarded as the oxidative stress index (OSI) (18).

#### Materials and Methods

The study included 21 BD cases who applied to outpatient clinic of Rheumatology Department of Internal Medicine of Medical Center of Firat University and 23 healthy individuals who age and sex matched. The diagnosis of BD was made according to the International Study Group's criteria for BD (19). The patients were divided into two groups, as active and inactive, depending on the activity of their disease identified in the

light of clinical and laboratory findings. The patients were interpreted as active if the patients with oral ulcer had at least two of below pathologies; genital ulcer, skin lesion, recent eye involvement, recent vascular involvement, recent neurological involvement, active arthritis, positive pathergy test and with high erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) (7,20,21). Histories of all individuals in the study were obtained, and systemic and rheumatological physical examinations were performed. Pathergy test was applied to all of the BD group, and 24-48 hours later, the patients were evaluated in terms of papulopustular lesions. All patients were assessed by an ophthalmologist for eye involvement. Approval of the local ethics committee and informed consent of the patients and healthy individuals were obtained. Patients with dyslipidemia, cardiovascular diseases, diabetes mellitus, renal failure, chronic infection, alcohol abuse, and who used antilipidemic and antioxidant drugs were excluded from the study.

Blood samples were obtained at 0800-0900 a.m. after 8-12 hours of fasting. The samples were centrifuged at 3000 rpm for 10 minutes to obtain serums. Ordinary biochemical assays were carried out in the serum samples in an Olympus AU 600 Autoanalyzer using Olympus kits (Olympus Corp. Tokyo-Japan). Erythrocyte sedimentation rate was determined by classical Westergren method immediately in whole blood with 1 mg/mL ethylene diamine tetraacetic acid. The level of CRP was determined by immunoturbidimetric technique (Schiapparelli Biosystems, the Netherlands).

The levels of serum total protein, albumin, bilirubin and uric acid were measured by using commercial kits (Olympus AU Autoanalyzer). TAR and TP, which are specific parameters, were measured using appropriate methods in the plasma samples obtained by centrifugation of blood put in heparinized tubes. Plasma samples were stored at -80 °C until the day of analysis.

**Measurement of the total antioxidant status of plasma:** The total antioxidant status of the plasma was measured using a novel automated colorimetric measurement method for the TAR developed by Erel (16,17). In this method the hydroxyl radical, the most potent biological radical, is produced by the Fenton reaction, and reacts with the colourless substrate O-dianisidine to produce the dianisyl radical, which is bright yellowish-brown in colour. Upon the addition of a plasma sample, the oxidative reactions initiated by the hydroxyl radicals present in the reaction mix are suppressed by the antioxidant components of the plasma, preventing the colour change and thereby providing an effective measure of the total antioxidant capacity of the plasma. The assay results are expressed as mmol Trolox eq./L, and the precision of this assay is excellent, being lower than 3% (22).

**Measurement of total plasma peroxide (TP) concentration:** The total plasma peroxide concentration were determined using the FOX2 method (23) with minor modifications (18). The FOX2 test system is based on the oxidation of ferrous iron to ferric iron by the various

types of peroxides contained in the plasma samples, in the presence of xylenol orange which produces a coloured ferric-xylenol orange complex whose absorbance can be measured. The FOX2 reagent was prepared by dissolving ammonium ferrous sulphate (9.8 mg) in 250 mM H<sub>2</sub>SO<sub>4</sub> (10 ml) to give a final concentration of 250 µM ferrous iron in acid. This solution was then added to 90 ml HPLC-grade methanol containing 79.2 mg butylated hydroxytoluene (BHT). Finally, 7.6 mg xylenol orange was added, with stirring, to make the working reagent (250 µM ammoniumferrous sulphate, 100 µM xylenol orange, 25 mM H<sub>2</sub>SO<sub>4</sub>, and 4 nM BHT, in 90% (v/v) methanol in a final volume of 100 ml). The blank reagent contained all the components of the solution except ferrous sulphate.

Aliquots (200 µL) of plasma were mixed with 1.8 ml FOX2 reagent. After incubation at room temperature for 30 min, the vials were centrifuged at 12,000 g for 10 min. The absorbance of the supernatant was then determined at 560 nm. The total peroxide content of the plasma samples was determined as a function of the difference in absorbance between the test and blank samples using a solution of H<sub>2</sub>O<sub>2</sub> as standard. The coefficient of variation for individual plasma samples was less than 5%.

**Oxidative stress index (OSI):** The ratio of the TP to the total antioxidant potential gave the oxidative stress index, an indicator of the degree of oxidative stress (18).

**Statistics:** All results were expressed as means ±SD. Student's t-test and Spearman's correlation analysis were performed using SPSS for Windows Release 11.0 (SPSS Inc. Chicago, Illinois, USA). The P value less than 0.05 was considered to be significant.


## Results

The patient group comprised 8 females and 13 males, whose mean age was 34,4±7,4 years and mean duration of disease was 3,7±2,9 years, while the control group consisted of 9 females and 14 males, whose mean age was 36,7±4,2 years. Demographical characteristics and laboratory findings of the BD group and the control group are presented in Table 1. There was not significant difference between patient and control groups in terms of age, gender, hemoglobin, white blood cell count (WBC), fasting blood glucose, total cholesterol, LDL, HDL and triglyceride values ( $p>0.05$ , for each). The comparison between the patient group and the control group showed that CRP level was significantly higher in the former ( $p<0.05$ ), and the ESR was higher, too, but the difference was not significant ( $p>0.05$ ).


Total protein level in the BD group was significantly higher when compared with the control group ( $p<0.05$ ). However, there was not any significant difference between the patient group and the control group with regard to individual antioxidants, which are albumin, bilirubin and uric acid ( $p>0.05$ , for each, Table 2).

TAR level was 1,04±0,07 and 1,16±0,08 mmol Trolox eq./L in the BD group and in the control group,


respectively; TP level was 13,4±4,5 and 7,72±1,86 µmol H<sub>2</sub>O<sub>2</sub>/L in the BD group and in the control group, respectively; OSI value was 1,45±0,52 and 0,67±0,18 Arbitrary Units in the BD group and in the control group, respectively. The comparison between the BD group and the control group revealed that the level of TAR was significantly lower and TP and OSI levels were significantly higher in the former ( $p<0.001$ , for each, Table 2, Figures 1 and 2).



**Figure 1.** The levels of TAR in the BD group and the control group.



**Figure 2.** TP and OSI values in the BD group and the control group.



**Figure 3.** Correlation graphics between the level of TAR and the level of TP in BD group (a) and control group (b).

**Table 1. Demographical characteristics and laboratory findings of the BD group and the control group.**

	BD (n:21)	Controls (n:23)	P
Age (years)	34,4±7,4	36,7±4,2	0.202
Sex (M/F)	13/8	14/9	0.892
Disease Duration (years)	3,7±2,9	-	-
BMI (Kg/m <sup>2</sup> )	24,2±3,4	24,1±3,1	0.941
Hemoglobin (gr/dL)	14,2±1,1	15,1±1,8	0.854
WBC (mm <sup>3</sup> )	8376±3497	7890±4215	0.675
ESR (mm/h)	19,7±11,4	12,5±8,9	0.452
CRP (mg/L)	21,5±23,2	3,2±2,3	0.022
Fasting blood glucose (mg/dL)	91,9±9,6	91,6±9,7	0.892
Total cholesterol (mg/dL)	175,8±38,9	170,3±31,4	0.810
LDL (mg/dL)	100,5±35,3	106,7±31,4	0.473
HDL (mg/dL)	44,7±11,3	47,9±9,2	0.390
Triglyceride (mg/dL)	134,5±69,6	145,6±77,8	0.320

M: male, F: female, BMI: body mass index, WBC; white blood cell count, ESR; erythrocyte sedimentation rate, CRP; C-reactive protein.

**Table 2. Antioxidant levels in the BD group and the control group.**

	BD (n:21)	Controls (n:23)	P
Uric Acid (mg/dL)	4,4±0,96	4,7±1,2	0.675
Total Bilirubin (mg/dL)	0,82±0,34	0,86±0,31	0.651
Direct Bilirubin (mg/dL)	0,11±0,08	0,10±0,04	0.202
Total Protein (gr/dL)	7,36±0,027	6,95±0,6	0.027
Albumin (gr/dL)	4,28±0,3	4,38±0,4	0.393
TAR (mmol Trolox eq./L)	1,04±0,07	1,16±0,08	0.000
TP (µmol H <sub>2</sub> O <sub>2</sub> /L)	13,4±4,5	7,72±1,86	0.000
OSI (Arbitrary Unit)	1,45±0,52	0,67±0,18	0.000

TAR; total antioxidant response, TP; total peroxide and OSI; oxidative stress index.

**Table 3. Clinical characteristics of patients with BD.**

Patient Number	Age (Years)	Sex (M/F)	Disease Duration (Years)	Oral Ulcers	Genital Lesions	Skin Lesions <sup>a</sup>	Ocular Lesions	Pathergy Test <sup>b</sup>
1	38	F	5	+		+	+	
2	44	M	6	+	+	+	+	
3	34	M	3	+		+		+
4 <sup>c</sup>	40	M	1	+	+	+		
5	41	F	1	+		+		+
6	40	F	3	+	+	+		
7	28	F	2	+	+	+		
8	32	M	9	+	+	+		+
9 <sup>c</sup>	26	M	1	+		+		+
10	23	M	2	+	+	+		
11	35	M	2	+	+	+	+	
12	45	M	5	+		+		+
13	31	F	1	+	+			+
14	27	F	1	+		+	+	
15	29	F	1	+	+	+		
16	22	M	3	+	+	+	+ <sup>d</sup>	
17	25	M	1	+		+		+
18	41	M	15	+			+	+
19	45	M	8	+	+	+		
20	37	M	4	+	+	+		
21	34	F	3	+		+		+

M=male, F=female. aacneiform and erythema nodosum-like lesions. bpathergy test, which is the examination of the injury caused by the tip of a needle in the forearm, 24-48 hours later with respect to papulopustular lesions. ccases who had vascular involvement in the form of venous thrombosis. doptic atrophy was found in addition to uveitis sequel in ophthalmologic examination.

The level of TAR was negatively correlated with TP (Figure 3) and OSI levels both in the BD group ( $r=-0.578$ ,  $p<0.01$  and  $r=-0.552$ ,  $p<0.01$ , respectively) and the control group ( $r=-0.469$ ,  $p<0.05$  and  $r=-0.391$ ,  $p<0.05$ , respectively). No significant correlation was found among duration of disease, and oxidant or antioxidant markers in the BD group ( $p>0.05$ , for each).

Of the cases in the BD group, 100% (n:21) had oral ulcer, 57,1% (n:12) genital ulcer or scar, 90,4% (n:19) skin lesion, 28,5% (n:6) ocular involvement, 9,5% (n:2) vascular involvement, 4,7% (n:1) neurological involvement and 42,8% (n:9) positive pathergy test (Table 3).

The comparison between the cases who had positive pathergy test and negative pathergy test and between the cases with and without ocular involvement did not show significant difference in terms of the laboratory findings evaluated ( $p > 0.05$ , for each). ESR was  $28,3 \pm 22,5$  and  $7,2 \pm 5,4$  mm/h and CRP level was  $40,3 \pm 23,6$  and  $4,2 \pm 1,5$  mg/L in the active (n:10) and inactive (n:11) BD groups, respectively. The increase in ESR and CRP in the active BD group was significant ( $p < 0.01$  and  $p < 0.05$ , respectively). However, the difference between active and inactive BD groups in terms of albumin, bilirubin, uric acid, TAR, TP and OSI levels was not significant ( $p > 0.05$ , for each).

## Discussion

It was shown that ROS and other oxidants could be also formed in the normal physiological process (2,3). It is known that activated inflammatory cells cause ROS production in BD a systemic, autoimmune disease (8). Increased ROS, in turn, enhance LPO products, thus, lead to tissue injury (2-7). H<sub>2</sub>O<sub>2</sub> and other derivatives of peroxides increase in some conditions, diffuse into plasma. Here, antioxidant components of plasma overwhelm them, and they are simultaneously consumed (15).

When TP is measured, it means that the sum of many peroxides like protein peroxide, lipid peroxide and H<sub>2</sub>O<sub>2</sub> are measured (24). Although it is known that H<sub>2</sub>O<sub>2</sub> and lipid peroxides increase in BD (3,5-7), oxidative stress has not been evaluated through TP in BD. However, it has been reported that TP level increases in passive smokers (25), preeclampsia cases (26) and cutaneous leishmaniasis (27). It was shown in the present study that TP level also increased in BD. Possible reasons for this increase in TP might be the inevitable increase in lipid peroxides and ROS including H<sub>2</sub>O<sub>2</sub> in BD.

Many antioxidant molecules found in blood prevent or inhibit the harmful effects of free radicals (15). Whenever there is a decrease in antioxidants and/or an increase in oxidants, oxidant/antioxidant balance is impaired in favor of oxidants and this is known as oxidative stress (24,28). It is known that oxidative stress is responsible for tissue injury in many diseases and contributes to the development of atherosclerosis (13,14). Antioxidant activity indicates the antioxidant characteristics of only one antioxidant, whereas total antioxidant capacity (TAC) represents the total antioxidant characteristics of all antioxidants found in the plasma. TAR and total antioxidant status (TAS) are used synonymously with TAC (28). It is doubtlessly more advantageous to evaluate TAR, instead of individual antioxidant activities. Many methods have been developed recently for this aim. Total radical trapping antioxidant parameter (TRAP), oxygen radical absorbance capacity (ORAC) and ferric reducing antioxidant power (FRAP) are colorimetric methods previously developed to assess TAC (16,17,28). It has been reported that TAR, a new measurement method developed by Erel (16,17) correlated with data obtained by other measurement methods and has had some extra advantages (16,17).

Blood has an important role in the oxidant/antioxidant balance, as it carries and distributes antioxidants through the body (28). Plasma has various antioxidant molecules. Albumin, uric acid, bilirubin and ascorbic acid are the major antioxidant components of plasma (16,17,28). TAR represents practically all of them (16,17). Albumin consists of about half of the TAC of the plasma (16,17). Albumin has several biological functions, particular as a ligand binder (29). Plasma thiol contents originate from albumin. Thiol groups, on the surface of albumin, bind oxidants (29). Low level of albumin can cause oxidative stress via leading to increase oxidants like homocystein (29). In chronic inflammation albumin is reduced. Bilirubin, a powerful endogenous antioxidant, is one of the catabolites of heme oxygenases (30). However, Harma et al. (26) have reported that bilirubin did not correlated with TAR, in their clinical study. Uric acid is another well-known low molecular weight water-soluble plasma antioxidant (16,17). Uric acid has a strong antioxidant activity and its concentration in the plasma is about 10 fold than antioxidants like vitamin C and vitamin E (28). In the present study, although there was a significant increase in total protein levels in the BD group, there was not any significant difference between the BD group and the control group in terms of the levels of such individual antioxidants as albumin, bilirubin and uric acid. It has been reported that total protein, bilirubin and uric acid levels correlated positively with TAC level (28). However, uric acid concentrations are influenced by age, diet, heavy exercise, renal failure and some metabolic diseases (28,31). Therefore, uric acid level may not appropriately reflect the TAC. However, it has been also reported that uric acid was not a strong antioxidant and might not protect against free radicals (32). Noyan et al. (21) have reported that while vitamin C levels reduced in BD oxidant MDA levels to be elevated, on the other hand, there is no changes in the levels of uric acid.

Orem et al. (6) have reported a decrease in TAR level in BD. Similarly, TAR level was found low in the BD group in the present study. The increase in TP and OSI levels and the negative correlation between these increases and TAR level in the present study suggest that a possible cause of the decrease in TAR level may be increased oxidative stress. Since albumin, bilirubin and uric acid levels were not significantly different between the BD and control groups in the present study, the decrease in TAR is not possible to attribute to only these individual antioxidants. Therefore, the decrease in TAR must have resulted from the decrease in other antioxidants. It has been reported that activity of PON1 (33) and level of SH (34), both of which are antioxidants, decreased in BD. Besides, Ece et al. (35) have noted that PON1 was positively correlated with TAR and negatively correlated with TP and OSI in cases with nephrotic syndrome. In the light of these data, a possible reason for the decrease in TAR in BD may be the decrease in other antioxidants, like PON1.

Plasma TAR level has been reported to be lower in those with CVD, compared with those without CVD, in smokers, compared with non-smokers, in diabetic cases,

compared with non-diabetic cases, and in hyperlipidemic cases, compared with those who have a normal lipid profile (36). Additionally, children who are exposed to passive cigarette smoking have been found to have a decrease in TAR level, and an increase in TP and OSI levels (25). It is known that oxidative stress is responsible for pathogenesis of atherosclerosis (37,38). As TAR is a fairly good representative of antioxidant capacity, and TP and OSI are representatives of oxidant capacity, decreased TAR and/or increased TP levels indicate oxidative stress (16,17,28). In the present study, there was a decrease in TAR level and an increase in TP and OSI levels in the BD group. In the light of these data, it is necessary to consider the possibility of development of atherosclerosis while evaluating BD cases.

In consideration of the fact that increased ROS and LPO products as a result of inflammation can be responsible for the impairment in oxidant/antioxidant balance, the increase in ROS and LPO products and the decrease in antioxidant capacity are expected to be more marked in the active BD group, in comparison to the

inactive BD group, due to marked inflammation. However, no significant difference was found between active and inactive BD groups with respect to TAR, TP, OSI, and levels of individual antioxidants, such as albumin, bilirubin and uric acid. This lack may be explained by the activity criteria used to determine the disease activity. It is known that currently there are no agreed activity criteria for BD. It is also possible that the oxidant/antioxidant balance is impaired at the onset of the disease and continues. In this study presented here, the fact that there is no relation between disease age and oxidant and antioxidant markers in the BD group may be supporting this theory.

In conclusion, TAR is an appropriate measurement method demonstrating oxidant/antioxidant balance. Oxidant/antioxidant balance seems to be impaired at all stages of BD. In future, we think that this argument should be confirmed by controlled, multi-centered, prospective studies, which shall include large case series and employ reviewed disease activity criteria.

## References

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. *N Engl J Med*. 1999; 341(17):1284-91.
2. Onder M, Gurer MA. The multiple faces of Behcet's disease and its aetiological factors. *J Eur Acad Dermatol Venereol*. 2001; 15(2):126-36.
3. Orem A, Efe H, Deger O, Cimsit G, Uydu HA, Vanizor B. Relationship between lipid peroxidation and disease activity in patients with Behcet's disease. *J Dermatol Sci*. 1997;16(1):11-6.
4. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome. *J Am Coll Cardiol*. 2001; 37(2):517-20.
5. Kokcam I, Naziroglu M. Effects of vitamin E supplementation on blood antioxidants levels in patients with Behcet's disease. *Clin Biochem*. 2002; 35(8):633-9.
6. Orem A, Yandi YE, Vanizor B, Cimsit G, Uydu HA, Malkoc M. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behcet's disease. *Clin Biochem*. 2002;35(3):217-24.
7. Yazici C, Kose K, Calis M, Demir M, Kirnap M, Ates F. Increased advanced oxidation protein products in Behcet's disease: a new activity marker. *Br J Dermatol*. 2004; 151(1):105-11.
8. Weiss SJ. Tissue destruction by neutrophils. *N Engl J Med*. 1989;320(6):365-76.
9. Saglam K, Serce AF, Yilmaz MI, et al. Trace elements and antioxidant enzymes in Behcet's disease. *Rheumatol Int*. 2002; 22(3):93-6.
10. Kose K, Yazici C, Cambay N, Ascioğlu O, Dogan P. Lipid peroxidation and erythrocyte antioxidant enzymes in patients with Behcet's disease. *Tohoku J Exp Med*. 2002; 197(1):9-16.
11. Dogan P, Tanrikulu G, Soyuer U, Kose K. Oxidative enzymes of polymorphonuclear leucocytes and plasma fibrinogen, ceruloplasmin, and copper levels in Behcet's disease. *Clin Biochem*. 1994; 27(5):413-8.
12. Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M. Auto-oxidative damage in Behcet's disease--endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. *Clin Exp Immunol*. 1982; 49(1):247-55.
13. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. *J Clin Invest*. 1991; 88(6):1785-92.
14. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. *Arterioscler Thromb*. 1994; 14(1):32-40.
15. Young IS, Woodside JV. Antioxidants in health and disease. *J Clin Pathol*. 2001; 54(3):176-86.
16. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. *Clin Biochem*. 2004; 37(4):277-85.
17. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. *Clin Biochem*. 2004; 37(2):112-9.
18. Harma M, Harma M, Erel O. Increased oxidative stress in patients with hydatidiform mole. *Swiss Med Wkly*. 2003; 133(41-42):563-6.

19. The International Study Group for Behcet's disease. Evaluation of diagnostic ('classification') criteria in Behcet's disease--towards internationally agreed criteria. *Br J Rheumatol.* 1992; 31(5):299-308.
20. Bekpinar S, Kilic N, Unlucerci Y, Akdag-Kose A, Azizlerli G, Ozbek-Kir Z. Evaluation of nitrosative and oxidative stress in Behcet disease. *J Eur Acad Dermatol Venereol.* 2005; 19(2):167-71.
21. Noyan T, Sahin I, Sekeroglu MR, Dulger H. The serum vitamin C levels in Behcet's disease. *Yonsei Med J.* 2003; 44(5):771-8.
22. Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. *Clin Chem.* 1998; 44(6 Pt 1):1309-15.
23. Miyazawa T, Saeki R, Inaba H. Detection of chemiluminescence in lipid peroxidation of biological systems and its application to HPLC. *J Biolumin Chemilumin.* 1989; 4(1):475-8.
24. Abuja PM, Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. *Clin Chim Acta.* 2001; 306(1-2):1-17.
25. Kosecik M, Erel O, Sevinc E, Selek S. Increased oxidative stress in children exposed to passive smoking. *Int J Cardiol.* 2005; 100(1):61-4.
26. Harma M, Harma M, Erel O. Measurement of the total antioxidant response in preeclampsia with a novel automated method. *Eur J Obstet Gynecol Reprod Biol.* 2005; 118(1):47-51.
27. Kocyigit A, Keles H, Selek S, Guzel S, Celik H, Erel O. Increased DNA damage and oxidative stress in patients with cutaneous leishmaniasis. *Mutat Res.* 2005; 585:71-8.
28. Ghiselli A, Serafini M, Natella F, Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. *Free Radic Biol Med.* 2000; 29(11):1106-14.
29. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, Jacobsen DW. Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. *J Biol Chem.* 2001; 276(50):46896-904.
30. Dohi K, Satoh K, Ohtaki H, et al. Elevated plasma levels of bilirubin in patients with neurotrauma reflect its pathophysiological role in free radical scavenging. *In Vivo.* 2005;19(5):855-60.
31. Puig JG, Mateos FA, Ramos TH, Capitan CF, Michan AA, Mantilla JM. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2). *Adv Exp Med Biol.* 1986; 195:317-23.
32. Smolenska Z, Kaznowska Z, Zarowny D, Simmonds HA, Smolenski RT. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. *Rheumatology (Oxford).* 1999; 38(10):997-1002.
33. Karakucuk S, Baskol G, Oner AO, Baskol M, Mirza E, Ustidal M. Serum paraoxonase activity is decreased in the active stage of Behcet's disease. *Br J Ophthalmol.* 2004; 88(10):1256-8.
34. Kose K, Dogan P, Ascioğlu M, Erkilic K, Ascioğlu O. Oxidative stress and antioxidant defenses in plasma of patients with Behcet's disease. *Tohoku J Exp Med.* 1995; 176(4):239-48.
35. Ece A, Atamer Y, Gurkan F, Davutoglu M, Kocyigit Y, Tutanc M. Paraoxonase, total antioxidant response, and peroxide levels in children with steroid-sensitive nephrotic syndrome. *Pediatr Nephrol.* 2005; 20(9):1279-84.
36. Demirbag R, Yilmaz R, Kocyigit A. Relationship between DNA damage, total antioxidant capacity and coronary artery disease. *Mutat Res.* 2005; 570(2):197-203.
37. Madamanchi NR, Hakim ZS, Runge MS. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. *J Thromb Haemost.* 2005; 3(2):254-67.
38. Violi F, Cangemi R. Antioxidants and cardiovascular disease. *Curr Opin Investig Drugs.* 2005; 6(9): 895-900.